Directly Observed Therapy for HIV Antiretroviral Therapy in an Urban US Setting [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 1, 2004, Pages 642-645

  Behforouz, Heidi L ^a   Kalmus, Audrey ^a   Scherz, China S ^a   Kahn, Jeffrey S ^a   Kadakia, Mitul B ^a   Farmer, Paul E ^a  

^a PARTNERS IN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL ARTICLE; DIRECTLY OBSERVED THERAPY; DRUG DOSE REGIMEN; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; NAUSEA; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; UNITED STATES; URBAN AREA; VIRUS LOAD; VOMITING;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMMUNITY HEALTH SERVICES; DIRECTLY OBSERVED THERAPY; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 2142640815     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200405010-00016     Document Type: Letter

References (14)

1. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and morality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338: 853-860.
2. Centers for Disease Control and Prevention. Atlanta, GA. Press Release: HIV diagnoses climbing among gay and bisexual men. Office of Communication. Media Relations. July 28, 2003. Available at: URL:http://www.cdc. gov/od/oc/media/pressrel/r030728.htm.
3. Bangsberg DR, Perry S, Charlebois ED, et al. Non adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
4. Moore RD, Stanton D, Gopalan R, et al. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763-768.
5. Lucas GM, Chiasson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antitretroviral therapy" a 5-year cohort study. J Acquir Immune Defic Syndr. 2003;33: 321-328.
6. th Interscience Congress on Antimicrobial Agents and Chemotherapy Symposium, September 28, 1997; Toronto, Ontario.
7. Frieden T, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City: turning the tide. N Engl J Med. 1995;333:229-233.
8. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001;110:664-666.
9. Lucas GM. Directly observed therapy for the treatment of HIV: promises and pitfalls. [Newspaper Article] The Hopkins HIV Report: a Bimonthly Newsletterfor Healthcare Providers. 2001;13:12-15.
10. Stenzel MS, McKenzie M, Mitty JA, et al. Enhancing adherence to ART: a pilot program of modified directly observed therapy. AIDS Reader. 2001;11:317-328.
11. Farmer PE, Léandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001; 358(9279):404-409.
12. World Health Organization Weekly Epidemiological Record 1994. World Health Organization, Geneva. 69:273-275.
13. First MB. ed. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association. Washington DC, 2000.
14. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999; 131:81-87.